This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why BioNTech SE Sponsored ADR (BNTX) Might be Well Poised for a Surge
by Zacks Equity Research
BioNTech SE Sponsored ADR (BNTX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Pfizer (PFE) Gets FDA Nod for Pneumococcal Vaccine Prevnar 20
by Zacks Equity Research
Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine candidate helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia.
Moderna (MRNA) Seeks Approval for COVID-19 Vaccine in Teens
by Zacks Equity Research
Moderna (MRNA) is seeking authorization for conditional use of its COVID-19 vaccine, mRNA-1273, in adolescents in Europe and Canada.
Can the Uptrend Continue for BioNTech (BNTX)?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor of BioNTech SE (BNTX).
Moderna (MRNA) Files for Full Approval of COVID-19 Vaccine
by Zacks Equity Research
Moderna (MRNA) seeks full approval for its COVID-19 vaccine, mRNA-1273, in adults with initiation of rolling submission of a BLA. The company also boosts manufacturing capacity for the vaccine.
J&J (JNJ) to Pay $2.5B in Baby Powder Case on Appeal Rejection
by Zacks Equity Research
The U.S. Supreme Court rejects J&J's (JNJ) appeal against a lower court verdict of $2.1 billion in damages in a litigation related to its talc-based baby powder.
Pfizer (PFE) COVID-19 Vaccine Gets Nod for Adolescents in EU
by Zacks Equity Research
Pfizer (PFE)/BioNTech (BNTX) vaccine turns out to be 100% effective in preventing COVID-19 in adolescents aged 12-15 years old.
What is Fair Value for the S&P500?
by John Blank
The latest earnings report season muddied the waters on that.
Is BioNTech SE Sponsored (BNTX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (BNTX) Outperforming Other Medical Stocks This Year?
Lumber Liquidators, Planet Fitness, Moderna, Pfizer and BioNTech highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Lumber Liquidators, Planet Fitness, Moderna, Pfizer and BioNTech highlighted as Zacks Bull and Bear of the Day
Here's Why Pfizer (PFE) Has Been Rallying This Year So Far
by Zacks Equity Research
Pfizer's (PFE) stock is up 5.8% this year, riding high on the success of its two-shot vaccine for COVID-19.
AbbVie's (ABBV) Venclyxto Gets EU Nod for First-Line AML
by Zacks Equity Research
European Commission grants approval to AbbVie (ABBV)/Roche's Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia
Moderna's (MRNA) COVID-19 Vaccine 100% Effective in Teens
by Zacks Equity Research
Moderna (MRNA) reports 100% efficacy of its COVID-19 vaccine in teenagers aged 12 to less than 18.
Pfizer (PFE) Tests COVID-19 Booster & Pneumococcal Vaccine Combo
by Zacks Equity Research
Pfizer's (PFE) study is testing its pneumococcal vaccine candidate along with COVID-19 booster shot on 600 fully vaccinated adults 60 years and older.
Lilly's (LLY) Tyvyt BLA Accepted for Review by FDA for NSCLC (Revised)
by Zacks Equity Research
Lilly (LLY) and Innovent's sintilimab, a PD-1 inhibitor, is marketed by the brand name of Tyvyt in China for two indications.
J&J's (JNJ) Amivantamab Gets FDA Nod for Rare Lung Cancer
by Zacks Equity Research
With the FDA nod, J&J's (JNJ) Rybrevant becomes the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC that targets EGFR exon 20 insertion mutations.
Zacks Industry Outlook Highlights: Moderna, Amgen, BioNTech, Repligen Corp and Ovid Therapeutics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Moderna, Amgen, BioNTech, Repligen Corp and Ovid Therapeutics
Pfizer/BioNTech to Supply 1.8B More Doses of Comirnaty in EU
by Zacks Equity Research
Pfizer (PFE)/BioNTech (BNTX) have a total supply order for 2.4 billion doses of its COVID-19 vaccine, Comirnaty in Europe.
Merck's (MRK) Pneumococcal Vaccine Succeeds in Pediatric Trials
by Zacks Equity Research
Merck's (MRK) 15-valent pneumococcal conjugate vaccine candidate, V114, demonstrates comparable immunogenicity and safety compared to a lower valency vaccine in infants and children.
Zacks Industry Outlook Highlights: Regeneron, Gilead Sciences, Amgen, Biogen, BioNTech, Repligen and Ovid Therapeutics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Regeneron, Gilead Sciences, Amgen, Biogen, BioNTech, Repligen and Ovid Therapeutics
Reata (RETA) Soars on Potential Omaveloxolone NDA Filing
by Zacks Equity Research
The FDA asks Reata (RETA) to submit a pre-NDA meeting request to discuss omaveloxolone study data and cancel its previous request for a more general Type C meeting, boosting chances of an early NDA filing.
Iovance (IOVA) Falls on Negative Lifileucel Regulatory Update
by Zacks Equity Research
Iovance (IOVA) announces delay in BLA submission for its lead pipeline candidate, lifileucel for metastatic melanoma due to potency assay issue.
3 Biotech Stocks to Keep an Eye On Amid the Coronavirus Mayhem
by Ekta Bagri
The focus on coronavirus treatments should maintain momentum for the volatile Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BNTX, RGEN and OVID to perform well.
Here's Why Ocugen (OCGN) Stock Has More Than Tripled This Year
by Zacks Equity Research
Ocugen's (OCGN) stock rides on the company's collaboration with India's Bharat Biotech to co-develop and commercialize the latter's COVID-19 vaccine, COVAXIN, for the U.S. market.
BioNTech (BNTX) Up More Than 100% So Far This Year: Here's Why
by Zacks Equity Research
BioNTech (BNTX) is riding high on the robust performance of its COVID-19 vaccine, BNT162b2, which has been developed in partnership with Pfizer.